Literature DB >> 16880075

Treatment of hepatitis C infection.

Rise Stribling1, Norman Sussman, John M Vierling.   

Abstract

HCV infection is one of the leading causes of chronic liver disease worldwide,and it results in cirrhosis, liver failure, and HCC. As a result, hepatitis C cirrhosis has become the principal indication for liver transplantation. Ironically,HCV infection can be cured with available antiviral therapies, but only a minority of infected persons has ever been treated. The current standard of therapy isa combination of PEG-IFNalpha and ribavirin, which produces high rates of SVRs(absence of detectable HCV RNA at least 24 weeks after cessation of therapy):42% to 56% in genotype 1 and 75% to 84% in genotypes 2 and 3. Recent reports indicate that the less frequent genotypes 4, 5, and 6 also are responsive to combination therapy. Recommendations for treatment of conventional and special patient populations were reviewed in detail. Newer therapeutics that are entering clinical trials provide hope that SVRs may be possible in patients who are difficult to treat and in nonresponders to current therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16880075     DOI: 10.1016/j.gtc.2006.05.003

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  4 in total

1.  Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism.

Authors:  Jonathan Goldwasser; Pazit Y Cohen; Wenyu Lin; Danny Kitsberg; Patrick Balaguer; Stephen J Polyak; Raymond T Chung; Martin L Yarmush; Yaakov Nahmias
Journal:  J Hepatol       Date:  2011-02-24       Impact factor: 25.083

Review 2.  Controversies in and challenges to our understanding of hepatitis C.

Authors:  Robert G Batey
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742

Review 3.  Syphilitic myositis: a case-based review.

Authors:  Elaine Yacyshyn; Praveena Chiowchanwisawakit; Derek J Emery; Jack Jhamandas; Lothar Resch; Geoffrey Taylor
Journal:  Clin Rheumatol       Date:  2011-01-07       Impact factor: 3.650

4.  Hepatitis C virus-mediated inhibition of cathepsin S increases invariant-chain expression on hepatocyte surface.

Authors:  Hangeun Kim; Budhaditya Mazumdar; Sandip K Bose; Keith Meyer; Adrian M Di Bisceglie; Daniel F Hoft; Ranjit Ray
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.